1. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference.
Diabetes Care 2014;37:2864–2883.
2. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy.
Diabetes 1983;32 Suppl 2:64–78.
3. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy.
J Am Soc Nephrol 2010;21:556–563.
4. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014.
JAMA 2016;316:602–610.
5. Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment.
J Am Soc Nephrol 2017;28:1023–1039.
6. Chagnac A, Zingerman B, Rozen-Zvi B, Herman-Edelstein M. Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity.
Nephron 2019;143:38–42.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications.
Nature 2001;414:813–820.
8. Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy.
Int J Mol Sci 2020;21:3798.
9. Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K. Diabetes and kidney disease: role of oxidative stress.
Antioxid Redox Signal 2016;25:657–684.
10. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling.
Mol Cell Endocrinol 2009;302:148–158.
11. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.
Diabetes 2005;54:1615–1625.
12. Ozbek E. Induction of oxidative stress in kidney.
Int J Nephrol 2012;2012:465897.
13. Rabbani N, Sebekova K, Sebekova K Jr, Heidland A, Thornalley PJ. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function.
Kidney Int 2007;72:1113–1121.
14. Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets.
Diabetes Obes Metab 2020;22 Suppl 1:16–31.
15. Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.
Nat Rev Nephrol 2019;15:327–345.
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
N Engl J Med 1993;329:1456–1462.
17. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 2001;345:861–869.
18. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med 2001;345:851–860.
19. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet 2008;372:547–553.
20. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
N Engl J Med 2013;369:1892–1903.
21. Takagi S, Li J, Takagaki Y, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.
J Diabetes Investig 2018;9:1025–1032.
22. Kamezaki M, Kusaba T, Komaki K, et al. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
Sci Rep 2018;8:4029.
23. Tanaka S, Sugiura Y, Saito H, et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Kidney Int 2018;94:912–925.
24. Körner A, Eklöf AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications.
Diabetes 1994;43:629–633.
25. Oshima M, Neuen BL, Jardine MJ, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Lancet Diabetes Endocrinol 2020;8:903–914.
26. Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition.
Cell Metab 2020;32:404–419.
27. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med 2019;380:2295–2306.
28. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease.
N Engl J Med 2020;383:1436–1446.
29. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na
+/H
+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.
Am J Physiol Renal Physiol 2009;297:F1647–F1655.
30. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
Diabetologia 2011;54:965–978.
31. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes.
N Engl J Med 2016;375:311–322.
32. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
N Engl J Med 2016;375:1834–1844.
33. Mann JF, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes.
N Engl J Med 2017;377:839–848.
34. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Endocrinol 2018;6:605–617.
35. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.
N Engl J Med 2021;385:896–907.
36. Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Kidney Int 2019;96:302–319.
37. Hou J, Xiong W, Cao L, Wen X, Li A. Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis.
Clin Ther 2015;37:2086–2103.
38. Ito S, Kashihara N, Shikata K, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial.
Clin J Am Soc Nephrol 2020;15:1715–1727.
39. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes.
N Engl J Med 2020;383:2219–2229.
40. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with Finerenone in kidney disease and type 2 diabetes.
N Engl J Med 2021;385:2252–2263.
41. Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis.
Physiol Rev 2018;98:1169–1203.
42. Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.
Kidney Int 2013;83:1029–1041.
43. Kobayashi EH, Suzuki T, Funayama R, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription.
Nat Commun 2016;7:11624.
44. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.
J Biol Chem 2006;281:35764–35769.
45. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
N Engl J Med 2011;365:327–336.
46. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
N Engl J Med 2013;369:2492–2503.
47. Chin MP, Wrolstad D, Bakris GL, et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
J Card Fail 2014;20:953–958.
48. Nangaku M, Kanda H, Takama H, Ichikawa T, Hase H, Akizawa T. Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI Study).
Kidney Int Rep 2020;5:879–890.
49. Rossing P, Block GA, Chin MP, et al. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Kidney Int 2019;96:1030–1036.
50. Ito M, Nangaku M. Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Kidney Int 2019;96:823–825.
51. Schildroth J, Rettig-Zimmermann J, Kalk P, et al. Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice.
Nephrol Dial Transplant 2011;26:779–789.
52. Fligny C, Barton M, Tharaux PL. Endothelin and podocyte injury in chronic kidney disease.
Contrib Nephrol 2011;172:120–138.
53. Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease.
Kidney Int 2014;86:896–904.
54. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy.
J Am Soc Nephrol 2010;21:527–535.
55. de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
J Am Soc Nephrol 2014;25:1083–1093.
56. Heerspink HJ, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Lancet 2019;393:1937–1947.
57. Donate-Correa J, Tagua VG, Ferri C, et al. Pentoxifylline for renal protection in diabetic kidney disease: a model of old drugs for new horizons.
J Clin Med 2019;8:287.
58. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.
J Am Soc Nephrol 2015;26:220–229.
59. Moreno JA, Izquierdo MC, Sanchez-Niño MD, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB.
J Am Soc Nephrol 2011;22:1315–1325.
60. Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, et al. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease.
Diabetes Care 2018;41:1817–1820.
61. Liles JT, Corkey BK, Notte GT, et al. ASK1 contributes to fibrosis and dysfunction in models of kidney disease.
J Clin Invest 2018;128:4485–4500.
62. Chertow GM, Pergola PE, Chen F, et al. Effects of selonsertib in patients with diabetic kidney disease.
J Am Soc Nephrol 2019;30:1980–1990.
63. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.
Am J Physiol Renal Physiol 2008;294:F697–F701.
64. Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials.
Expert Opin Investig Drugs 2016;25:1045–1058.
65. de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
Lancet Diabetes Endocrinol 2015;3:687–696.
66. Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.
Diabetes 2009;58:469–477.
67. Zhang H, Nair V, Saha J, et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.
Kidney Int 2017;92:909–921.
68. Lu TC, Wang ZH, Feng X, et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy.
Kidney Int 2009;76:63–71.
69. Tuttle KR, Brosius FC 3rd, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial.
Nephrol Dial Transplant 2018;33:1950–1959.
70. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy.
J Am Soc Nephrol 2010;21:763–772.
71. Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP. Soluble guanylate cyclase stimulators and activators.
Handb Exp Pharmacol 2021;264:355–394.
72. Krishnan SM, Kraehling JR, Eitner F, Bénardeau A, Sandner P. The impact of the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective.
Int J Mol Sci 2018;19:1712.
73. Harloff M, Prüschenk S, Seifert R, Schlossmann J. Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
Br J Pharmacol 2022;179:2460–2475.
74. Czirok S, Fang L, Radovits T, et al. Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats.
Sci Rep 2017;7:11218.
75. Hanrahan JP, de Boer IH, Bakris GL, et al. Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial.
Clin J Am Soc Nephrol 2020;16:59–69.
76. Hasegawa S, Tanaka T, Saito T, et al. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Kidney Int 2020;97:934–950.
77. Sugahara M, Tanaka S, Tanaka T, et al. Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice.
J Am Soc Nephrol 2020;31:560–577.